Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AP32788: Phase I/II started

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: AP32788 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR); Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) …

    Published on 6/27/2016
  • Arimoclomol: Phase III started

    Orphazyme ApS, Copenhagen, Denmark Product: Arimoclomol (OR-01) Business: Endocrine/Metabolic Molecular target: Heat shock protein 70 (Hsp70) Description: Small molecule inducer of heat shock protein Indication: Treat …

    Published on 6/27/2016
  • Brilacidin: Phase II started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin Business: Autoimmune Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic given via retention enema Indication: Treat …

    Published on 6/27/2016
  • CTX DP: Completed Phase II enrollment

    ReNeuron Group plc (LSE:RENE), Pencoed, U.K. Product: CTX DP, CTX stem cells (formerly ReN001) Business: Neurology Molecular target: Not applicable Description: Allogeneic human neural stem cells derived from ReNeurons …

    Published on 6/27/2016
  • D-JNKI-1: Phase III started

    Auris Medical Holding AG (NASDAQ:EARS), Zug, Switzerland Xigen S.A., Epalinges, Switzerland Product: D-JNKI-1 (XG-102, AM-111) Business: Other Molecular target: c-jun N-terminal kinase (JNK) Description: C-jun N-…

    Published on 6/27/2016
  • Ezutromid: Phase II started

    Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: Ezutromid (formerly SMT C1100, BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule utrophin (UTRN) …

    Published on 6/27/2016
  • FLX-787: Phase II started

    Flex Pharma Inc. (NASDAQ:FLKS), Boston, Mass. Product: FLX-787 Business: Autoimmune Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1); Transient receptor potential A1 (TRPA1) Description: …

    Published on 6/27/2016
  • Fovista pegpleranib: Completed Phase III enrollment

    Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Fovista pegpleranib (formerly E10030) Business: Ophthalmic Molecular target: Platelet derived growth factor B…

    Published on 6/27/2016
  • GBT440: Phase IIa started

    Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco, Calif. Product: GBT440 Business: Pulmonary Molecular target: Hemoglobin Description: Allosteric modifier of hemoglobin oxygen affinity Indication: Treat …

    Published on 6/27/2016
  • MBN-101: Phase IIa started

    Haisco Pharmaceutical Group Co. Ltd. (SZSE:002653), Chengdu, China Microbion Corp., Bozeman, Mont. Product: MBN-101 (formerly BisEDT Antimicrobial Gel) Business: Infectious Molecular target: NA Description: Topical gel …

    Published on 6/27/2016
  • NFC-1: Phase II/III started

    Medgenics Inc. (NYSE-M:MDGN), Wayne, Pa. Product: NFC-1 Business: Neurology Molecular target: Metabotropic glutamate receptors (mGluR) Description: Small molecule agonist of metabotropic glutamate receptor subtype 1 (…

    Published on 6/27/2016
  • NGM313: Phase I started

    NGM Biopharmaceuticals Inc., South San Francisco, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: NGM313 Business: Endocrine/Metabolic Molecular target: Fibroblast growth factor (FGF) receptor 1c isoform (…

    Published on 6/27/2016
  • Norovirus VLP intramuscular vaccine: Phase IIb started

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Norovirus VLP intramuscular vaccine (TAK-214) Business: Infectious Molecular target: Not applicable Description: Bivalent virus-like particle (VLP) …

    Published on 6/27/2016
  • Oral lasmiditan: Completed Phase III enrollment

    CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), Durham, N.C. Product: Oral lasmiditan (Oral COL-144) Business: Neurology Molecular target: Serotonin (5-HT1F) receptor Description: Selective agonist of serotonin (5-HT1F) …

    Published on 6/27/2016
  • Resunab: Completed Phase II enrollment

    Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), Norwood, Mass. Product: Resunab (JBT-101) Business: Autoimmune Molecular target: Cannabinoid CB2 receptor (CNR2) Description: Synthetic cannabinoid CB2 receptor (CNR2)…

    Published on 6/27/2016
  • SCIB1: Phase I/II halted

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K. Product: SCIB1 Business: Cancer Molecular target: Tyrosinase-related protein 2 (TRP-2) (TYRP2) (DCT) Description: Cancer vaccine comprising the melanoma …

    Published on 6/27/2016
  • ST266: Phase II started

    Noveome Biotherapeutics Inc., Pittsburgh, Pa. Product: ST266 Business: Dental Molecular target: NA Description: Secretome solution designed to enhance paracrine signaling pathways Indication: Treat moderate to severe …

    Published on 6/27/2016
  • SynCon Zika DNA vaccine: Phase I start

    GeneOne Life Science Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon Zika DNA vaccine (GLS-5700) Business: Infectious Molecular target: NA Description: …

    Published on 6/27/2016
  • Tipifarnib: Phase II started

    Kura Oncology Inc. (NASDAQ:KURA), Glendale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tipifarnib (formerly Zarnestra) Business: Cancer Molecular target: Farnesyl transferase Description: Farnesyl…

    Published on 6/27/2016
  • Toraymyxin: Completed Phase III enrollment

    Spectral Medical Inc. (TSX:EDT; OTCQX:EDTXF), Toronto, Ontario Product: Toraymyxin (polymyxin B immobilized fiber column) Business: Infectious Molecular target: NA Description: Hemoperfusion absorption column made of …

    Published on 6/27/2016
  • TPIV200/huFR-1: Phase II started

    TapImmune Inc. (OTCQB:TPIV), Jacksonville, Fla. Product: TPIV200/huFR-1 (TPIV 200) Business: Cancer Molecular target: Folate receptor 1 (FOLR1) (FR-alpha) Description: Multi-epitope folate receptor 1 (FOLR1; FR-alpha) …

    Published on 6/27/2016
  • ZEN-3694: Phase I started

    Zenith Epigenetics Corp., Calgary, Alberta Product: ZEN-3694 Business: Cancer Molecular target: Bromodomain containing 4 (BRD4); BET bromodomain proteins Description: Small molecule inhibitor of BET bromodomain proteins…

    Published on 6/27/2016
  • ZP-Triptan: Pivotal trial started

    Zosano Pharma Corp. (NASDAQ:ZSAN), Fremont, Calif. Product: ZP-Triptan Business: Neurology Molecular target: Serotonin (5-HT1B) receptor; Serotonin (5-HT1D) receptor Description: Zolmitriptan, a serotonin (5-HT1B) and 5…

    Published on 6/27/2016
  • ABP-700: Phase II started

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Product: ABP-700 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: General anesthesia…

    Published on 6/20/2016
  • AGS-003: Phase III ongoing

    Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Product: AGS-003 Business: Cancer Molecular target: Not applicable Description: Second-generation RNA-loaded autologous dendritic cell immunotherapy Indication: Treat …

    Published on 6/20/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993